NCBI

PubMed

| All Databases | PubMed | Nucleotide | Protein | Genome | Structure | OMIM | PMC | Journals | Bool |

Search PubMed for vasopressin receptor antagonist   Preview Go Clea

Limits   Preview/Index   **History**   Clipboard   Details

- Search History will be lost after eight hours of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.
- Click on query # to add to strategy

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI (Cubby)

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Search	Most Recent Queries	Time	Result
#1 Search **vasopressin receptor antagonist** Sort by: **PublicationDate**		13:53:10	1020

Clear History

Jun 6 2005 07:23:23

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653adk

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1   Web Page URLs for STN Seminar Schedule - N. America
NEWS 2   "Ask CAS" for self-help around the clock
NEWS 3 FEB 25   CA/CAPLUS - Russian Agency for Patents and Trademarks
                  (ROSPATENT) added to list of core patent offices covered
NEWS 4 FEB 28   PATDPAFULL - New display fields provide for legal status
                  data from INPADOC
NEWS 5 FEB 28   BABS - Current-awareness alerts (SDIs) available
NEWS 6 FEB 28   MEDLINE/LMEDLINE reloaded
NEWS 7 MAR 02   GBFULL: New full-text patent database on STN
NEWS 8 MAR 03   REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS 9 MAR 03   MEDLINE file segment of TOXCENTER reloaded
NEWS 10 MAR 22   KOREAPAT now updated monthly; patent information enhanced
NEWS 11 MAR 22   Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS 12 MAR 22   PATDPASPC - New patent database available
NEWS 13 MAR 22   REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS 14 APR 04   EPFULL enhanced with additional patent information and new
                  fields
NEWS 15 APR 04   EMBASE - Database reloaded and enhanced
NEWS 16 APR 18   New CAS Information Use Policies available online
NEWS 17 APR 25   Patent searching, including current-awareness alerts (SDIs),
                  based on application date in CA/CAplus and USPATFULL/USPAT2
                  may be affected by a change in filing date for U.S.
                  applications.
NEWS 18 APR 28   Improved searching of U.S. Patent Classifications for
                  U.S. patent records in CA/CAplus
NEWS 19 MAY 23   GBFULL enhanced with patent drawing images
NEWS 20 MAY 23   REGISTRY has been enhanced with source information from
                  CHEMCATS
NEWS 21 MAY 26   STN User Update to be held June 6 and June 7 at the SLA 2005
                  Annual Conference
NEWS 22 JUN 06   STN Patent Forums to be held in June 2005
NEWS 23 JUN 06   The Analysis Edition of STN Express with Discover!
                  (Version 8.0 for Windows) now available

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
              MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
              AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS   STN Operating Hours Plus Help Desk Availability
NEWS INTER   General Internet Information
NEWS LOGIN   Welcome Banner and News Items
NEWS PHONE   Direct Dial and Telecommunication Network Access to STN
NEWS WWW   CAS World Wide Web Site (general information)

      506   FILE EMBASE
      108   FILE ESBIOBASE
  17 FILES SEARCHED...
       23   FILE IFIPAT
        2   FILE IMSDRUGNEWS
        2   FILE IPA
       16   FILE JICST-EPLUS
       27   FILE LIFESCI
      184   FILE MEDLINE
        5   FILE NLDB
       97   FILE PASCAL
        4   FILE PHARMAML
        2   FILE PHIN
      192   FILE SCISEARCH
       77   FILE TOXCENTER
       67   FILE USPATFULL
        8   FILE USPAT2

   27 FILES HAVE ONE OR MORE ANSWERS,   38 FILES SEARCHED IN STNINDEX

L1   QUE VASOPRESSIN RECEPTOR ANTAGONIST

=> d rank
F1   506   EMBASE
F2   313   CAPLUS
F3   238   BIOSIS
F4   192   SCISEARCH
F5   184   MEDLINE
F6   108   ESBIOBASE
F7   97   PASCAL
F8   77   TOXCENTER
F9   67   USPATFULL
F10   65   DRUGU
F11   60   BIOTECHNO
F12   58   DDFU
F13   27   LIFESCI
F14   23   IFIPAT
F15   16   JICST-EPLUS
F16   15   ADISCTI
F17   8   USPAT2
F18   5   ADISINSIGHT
F19   5   NLDB
F20   4   CANCERLIT
F21   4   PHARMAML
F22   3   ADISNEWS
F23   3   DISSABS
F24   2   IMSDRUGNEWS
F25   2   IPA
F26   2   PHIN
F27   1   EMBAL

=> index f1-f27
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                              ENTRY   SESSION
FULL ESTIMATED COST   1.18   1.98

INDEX 'EMBASE, CAPLUS, BIOSIS, SCISEARCH, MEDLINE, ESBIOBASE, PASCAL, TOXCENTER,
      USPATFULL, DRUGU, BIOTECHNO, DDFU, LIFESCI, IFIPAT, JICST-EPLUS, ADISCTI,
      USPAT2, ADISINSIGHT, NLDB, CANCERLIT, PHARMAML, ADISNEWS, DISSABS,

   * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:22:53 ON 13 JUN 2005

=> index medicine
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                              ENTRY   SESSION
FULL ESTIMATED COST   0.21   0.21

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CANCERLIT, CAPLUS,
      CEN, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE,
      ESBIOBASE, IFIPAT, IMSDRUGNEWS, IMSPRODUCT, IPA, JICST-EPLUS, KOSMET,
      LIFESCI, MEDICONF, MEDLINE, NAPRALERT, ...' ENTERED AT 13:23:05 ON 13 JUN
2005

39 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> index medicine -dgene
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                              ENTRY   SESSION
FULL ESTIMATED COST   0.59   0.80

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CANCERLIT, CAPLUS,
      CEN, DDFB, DDFU, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE,
      ESBIOBASE, IFIPAT, IMSDRUGNEWS, IMSPRODUCT, IPA, JICST-EPLUS, KOSMET,
      LIFESCI, MEDICONF, MEDLINE, NAPRALERT, ...' ENTERED AT 13:23:14 ON 13 JUN
2005

38 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s vasopressin receptor antagonist
      15   FILE ADISCTI
       5   FILE ADISINSIGHT
       3   FILE ADISNEWS
     238   FILE BIOSIS
      60   FILE BIOTECHNO
       4   FILE CANCERLIT
     313   FILE CAPLUS
      58   FILE DDFU
       3   FILE DISSABS
      65   FILE DRUGU
       1   FILE EMBAL

     IMSDRUGNEWS, IPA, PHIN, EMBAL' ENTERED AT 13:24:16 ON 13 JUN 2005

27 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> l1 and (ear or vertigo or tinnitus or hydrops)
       5   FILE EMBASE
       3   FILE CAPLUS
       1   FILE TOXCENTER
      13   FILE USPATFULL
  10 FILES SEARCHED...
       3   FILE IFIPAT
       3   FILE USPAT2
  25 FILES SEARCHED...

   6 FILES HAVE ONE OR MORE ANSWERS,   27 FILES SEARCHED IN STNINDEX

L2   QUE L1 AND (EAR OR VERTIGO OR TINNITUS OR HYDROPS)

=> d rank
F1   13   USPATFULL
F2   5   EMBASE
F3   3   CAPLUS
F4   3   IFIPAT
F5   3   USPAT2
F6   1   TOXCENTER

=> file f1-f6
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                              ENTRY   SESSION
FULL ESTIMATED COST   1.18   3.16

FILE 'USPATFULL' ENTERED AT 13:25:42 ON 13 JUN 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 13:25:42 ON 13 JUN 2005
COPYRIGHT (C) 2005 Elsevier Inc. All rights reserved.

FILE 'CAPLUS' ENTERED AT 13:25:42 ON 13 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'IFIPAT' ENTERED AT 13:25:42 ON 13 JUN 2005
COPYRIGHT (C) 2005 IFI CLAIMS(R) Patent Services (IFI)

FILE 'USPAT2' ENTERED AT 13:25:42 ON 13 JUN 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 13:25:42 ON 13 JUN 2005
COPYRIGHT (C) 2005 ACS

=> l2

L3   28 L2

=> dup rem l3

```
PROCESSING COMPLETED FOR L3
L4        20 DUP REM L3 (8 DUPLICATES REMOVED)

=> 14 and (pd<20000703 or prd<20000703)
'20000703' NOT A VALID FIELD CODE
   2 FILES SEARCHED...
   5 FILES SEARCHED...
'20000703' NOT A VALID FIELD CODE
L5         5 L4 AND (PD<20000703 OR PRD<20000703)

=> d 15 1-5 ibib kwic
```

```
L5   ANSWER 1 OF 5  USPATFULL on STN
ACCESSION NUMBER:    2002:317425  USPATFULL  Full-text
TITLE:               Nonpeptide substituted benzothiazepines as vasopressin
                     antagonists
INVENTOR(S):         Urbanski, Maud J., Belle Mead, NJ, United States
                     Chen, Robert H. K., Belle Mead, NJ, United States
PATENT ASSIGNEE(S):  Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ, United
                     States (U.S. corporation)

                        NUMBER      KIND    DATE
                     ---------------- ------ --------
PATENT INFORMATION:  US 6489321      B1    20021203
APPLICATION INFO.:   US 2000-704314        20001102  (9)

                        NUMBER      DATE
                     ------------------ --------
PRIORITY INFORMATION: US 1999-163544P  19991104 (60)          <--
DOCUMENT TYPE:       Utility
FILE SEGMENT:        GRANTED
PRIMARY EXAMINER:    Kifle, Bruck
NUMBER OF CLAIMS:    27
EXEMPLARY CLAIM:     1
NUMBER OF DRAWINGS:  0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT:          1558
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
PRAI  US 1999-163544P    19991104 (60)                <--
AB        wherein A, X, Z, Bp, W, n, R.sup.1 and R.sup.2 are as described in the
          specification, which are useful as vasopressin receptor antagonists for
          treating conditions involving increased vascular resistance and cardiac
          insufficiency. Pharmaceutical compositions comprising a compound of Formula
          I and methods.  .  .
SUMM      This invention relates to novel nonpeptide substituted
          vasopressin receptor antagonists. More
          particularly, the compounds of the present invention interrupt the
          binding of the peptide hormone vasopressin to its receptors and.  .  .
SUMM      .  .  .  receptor in the vasculature, vasopressin V-1 antagonists have
          reduced blood pressure as a potential treatment for hypertension as
          well. Thus, vasopressin receptor antagonists
          could be useful as therapeutics in the conditions of hypertension,
          congestive heart failure/cardiac insufficiency, coronary vasospasm,
          cardiac ischemia, liver cirrhosis,.  .  .
SUMM      The compounds of the present invention are vasopressin
          receptor antagonists useful as aquaretics and, in
          general, in disease states of vascular resistance.
SUMM      .  .  .  of any of the compounds described above for the preparation of
          a medicament for treating a condition selected from inner ear
          disorders, hypertension, congestive heart failure, cardiac
          insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis,
```

```
          nonhuman
          controlled study
          animal tissue
          article
          priority journal
          *vasopressin: PD, pharmacology
          vasoconstrictor agent: PD, pharmacology
          desmopressin: PD, pharmacology
            vasopressin receptor antagonist: PD, pharmacology
          vasopressin v1 receptor: EC, endogenous compound
          pyridoxal phosphate 6 azophenyl 2',4' disulfonic acid: PD, pharmacology
          phentolamine: PD, pharmacology
          prazosin: PD,. . .
```

```
L5   ANSWER 3 OF 5  EMBASE  COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.
     on STN
ACCESSION NUMBER:    97153829 EMBASE  Full-text
DOCUMENT NUMBER:     1997153829
TITLE:               Role of vasopressin in essential hypertension: Racial
                     differences.
AUTHOR:              Bakris G.; Bursztyn M.; Gavras I.; Bresnahan M.; Gavras H.
CORPORATE SOURCE:    Dr. G. Bakris, Rush Hypertension Center,
                     Rush-Presbyterian-St Luke's Med Ctr, 1725 W Harrison
                     Street, Chicago, IL 60612, United States
SOURCE:              Journal of Hypertension, (1997) Vol. 15, No. 5,
                     pp. 545-550.
                     Refs: 31
                     ISSN: 0263-6352  CODEN: JOHYD3
COUNTRY:             United Kingdom
DOCUMENT TYPE:       Journal; Article
FILE SEGMENT:        006     Internal Medicine
                     017     Public Health, Social Medicine and Epidemiology
                     018     Cardiovascular Diseases and Cardiovascular Surgery
                     037     Drug Literature Index
                     038     Adverse Reactions Titles
LANGUAGE:            English
SUMMARY LANGUAGE:    English
ENTRY DATE:          Entered STN: 970612
                     Last Updated on STN: 970612
SO   Journal of Hypertension, (1997) Vol. 15, No. 5, pp. 545-550.
     Refs: 31
     ISSN: 0263-6352  CODEN: JOHYD3
AB   .  .  .  subjects (16 Caucasian, 23 African-American) eating a 200 mmol/day
     sodium diet were administered a single intravenous dose of a selective
     vasopressin receptor antagonist and their blood pressure was monitored
     constantly for the ensuing 3 h. The protocol was repeated 3 days later after.
     . .
CT   Medical Descriptors:
     *essential . . . article
     clinical protocol
     clinical trial
     controlled study
     female
     headache: SI, side effect
     human
     intravenous drug administration
     male
     mean arterial pressure
     negro
     oral drug administration
```

```
          renal vasospasm, renal failure, cerebral edema and.  .  .
SUMM      The nonpeptide substituted benzodiazepine compounds of the present
          invention are vasopressin receptor
          antagonists, in a preferred embodiment, the compounds are orally
          active. As demonstrated by the results of the pharmacological studies
          described hereinafter,.  .  .
CLM       What is claimed is:
          21. The method of claim 20 wherein said condition is selected from inner
          ear disorders, hypertension, congested heart failure, cardiac
          insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis,
          renal vasospasm, renal failure, cerebral edema and.  .  .
```

```
L5   ANSWER 2 OF 5  EMBASE  COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.
     on STN
ACCESSION NUMBER:    1999068089 EMBASE  Full-text
TITLE:               Effects of vasopressin on the sympathetic contraction of
                     rabbit ear artery during cooling.
AUTHOR:              Garcia-Villalon A.L.; Padilla J.; Monge L.; Fernandez N.;
                     Sanchez M.A.; Gomez B.; Dieguez G.
CORPORATE SOURCE:    G. Dieguez, Departamento de Fisiologia, Facultad de
                     Medicina, Universidad Autonoma, Arzobispo Morcillo 2, 28029
                     Madrid, Spain. godofredo.dieguez@uam.es
SOURCE: .            British Journal of Pharmacology, (1999) Vol. 126,
                     No. 3, pp. 785-793.
                     Refs: 22
                     ISSN: 0007-1188  CODEN: BJPCBM
COUNTRY:             United Kingdom
DOCUMENT TYPE:       Journal; Article
FILE SEGMENT:        030     Pharmacology
                     037     Drug Literature Index
LANGUAGE:            English
SUMMARY LANGUAGE:    English
ENTRY DATE:          Entered STN: 19990304
                     Last Updated on STN: 19990304
TI   Effects of vasopressin on the sympathetic contraction of rabbit
     ear artery during cooling.
SO   British Journal of Pharmacology, (1999) Volume 126, Number 3, pp.
     785-793.
     Refs: 22
     ISSN: 0007-1188 CODEN: BJPCBM
AB   .  .  .  the vascular contraction to sympathetic nerve stimulation during
     cooling, the isometric response of isolated, 2-mm segments of the rabbit
     central ear (cutaneous) artery to electrical field stimulation (1-8 Hz) was
     recorded at 37 and 30°C. 2.  Electrical stimulation (37°C) produced frequency-
     dependent.  .  .  it did not modify the contraction to noradrenaline (1 µM) at
     either temperature. 6.  These results suggest that in cutaneous (ear)
     arteries, vasopressin potentiates sympathetic vasoconstriction to a greater
     extent at 30 than at 37°C by activating vasopressin V1 receptors and.  .  .
CT   Medical Descriptors:
     *sympathetic tone
     *artery constriction
       *ear artery
     *cooling
     rabbit
     sympathetic nerve
     muscle isometric contraction
     electric field
     temperature
     vascular endothelium
     calcium channel
```

```
          plasma renin activity  .
          pressor response
          priority journal
          race difference
          receptor blocking
          vasopressin blood level
            vertigo: SI, side effect
          *argipressin: EC, endogenous compound
          *vasopressin: EC, endogenous compound
          clonidine: AD, drug administration
          clonidine: DT, drug therapy
          renin: EC, endogenous compound
          vasopressin antagonist:.  .  .
```

```
L5   ANSWER 4 OF 5  EMBASE  COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.
     on STN
ACCESSION NUMBER:    91269291 EMBASE  Full-text
DOCUMENT NUMBER:     1991269291
TITLE:               The influence of intra-arterial infusion of arginine
                     vasopressin on cochlear blood flow in the rat.
AUTHOR:              McLaren G.M.; Coleman J.K.M.; Quirk W.S.; Dengerink H.A.;
                     Wright J.W.
CORPORATE SOURCE:    Department of Psychology, Washington State
                     University, Pullman, WA 99164-4820, United States
SOURCE:              Hearing Research, (1991) Vol. 55, No. 1, pp. 1-8.
                     ISSN: 0378-5955  CODEN: HERED3
COUNTRY:             Netherlands
DOCUMENT TYPE:       Journal; Article
FILE SEGMENT:        011     Otorhinolaryngology
                     037     Drug Literature Index
LANGUAGE:            English
SUMMARY LANGUAGE:    English
ENTRY DATE:          Entered STN: 911216
                     Last Updated on STN: 911216
SO   Hearing Research, (1991) Vol. 55, No. 1, pp. 1-8.
     ISSN: 0378-5955  CODEN: HERED3
AB   .  .  .  mediated by the interaction of vasoactive peptides such as AVP and
     its receptors located in the vasculature of the inner ear or in the more
     peripheral vessels directly supplying the cochlea.
CT   Medical Descriptors:
     *blood pressure
     *cochlea blood flow
     aged
     animal experiment
     article
     controlled study
     intraarterial drug administration
     laser doppler flowmetry
     major clinical study
     nonhuman
     priority journal
     rat
     *argipressin: PD, pharmacology
     *argipressin: DO, drug dose
       vasopressin receptor antagonist: PD, pharmacology
```

```
L5   ANSWER 5 OF 5  CAPLUS  COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER:       1999:307414  CAPLUS  Full-text
DOCUMENT NUMBER:        130:306609
TITLE:                  Use of vasopressin antagonists
```

INVENTOR(S):   Zenner, Hans Peter; Ruppersberg, J.-Peter; Loewenheim,
                          Hubert
PATENT ASSIGNEE(S):   Germany
SOURCE: Ger. Offen., 12 pp.
                          CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

```
       PATENT NO.        KIND  DATE      APPLICATION NO.        DATE
       --------------    ----  --------  --------------------   --------
       DE 19748763       A1    19990506  DE 1997-19748763       19971105 <--
       CA 2309117        AA    19990520  CA 1998-2309117        19981104 <--
       WO 9924051        A2    19990520  WO 1998-EP7033         19981104 <--
       WO 9924051        A3    19990701
           W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
               DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE,
               KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,
               MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
               TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
          RW:  GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
               FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
               CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
       AU 9917536        A1    19990531  AU 1999-17536          19981104 <--
       EP 1028725        A1    20000823  EP 1998-962320         19981104 <--
       EP 1028725        B1    20040211
           R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
               IE, FI
       BR 9813957        A     20000926  BR 1998-13957          19981104 <--
       JP 2001522807     T2    20011120  JP 2000-520139         19981104 <--
       AT 259230         E     20040215  AT 1998-962320         19981104 <--
       ES 2218875        T3    20041116  ES 1998-962320         19981104 <--
PRIORITY APPLN. INFO.:                   DE 1997-19748763    A  19971105 <--
                                         WO 1998-EP7033      W  19981104 <--
PI  DE 19748763 A1 19990506
       PATENT NO.        KIND  DATE      APPLICATION NO.        DATE
       --------------    ----  --------  --------------------   --------
PI  DE 19748763          A1    19990506  DE 1997-19748763       19971105 <--
    CA 2309117           AA    19990520  CA 1998-2309117        19981104 <--
    WO 9924051           A2    19990520  WO 1998-EP7033         19981104 <--
    WO 9924051           A3    19990701
           W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
               DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE,
               KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,
               MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
               TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
          RW:  GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
               FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
               CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
       AU 9917536        A1    19990531  AU 1999-17536          19981104 <--
       EP 1028725        A1    20000823  EP 1998-962320         19981104 <--
       EP 1028725        B1    20040211
           R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
               IE, FI
       BR 9813957        A     20000926  BR 1998-13957          19981104 <--
       JP 2001522807     T2    20011120  JP 2000-520139         19981104 <--
       AT 259230         E     20040215  AT 1998-962320         19981104 <--
       ES 2218875        T3    20041116  ES 1998-962320         19981104 <--
PRAI DE 1997-19748763    A     19971105 <--
```

WO 1998-EP7033   W   19981104 <--
AB   Vasopressin receptor antagonists, esp. V2 receptor antagonists, are useful for
     treatment of inner ear disorders associated with vertigo, deafness, and/or
     tinnitus as in Meniere's disease, evidently by increasing the water
     permeability of the endolymphatic sac in cases involving endolymphatic
     hydrops. Thus, 125I-labeled arginine-vasopressin bound to the human
     endolymphatic sac epithelium, which expressed genes for both V2 receptors and
     the water channel glycoprotein aquaporin-2. Vasopressin caused endolymphatic
     hydrops in guinea pigs, as indicated by displacement of Reissner's membrane.
     Administration of the peptide V2 receptor antagonist, H-9400, to cultured rat
     endolymphatic sac epithelium reversed the vasopressin-induced inhibition of
     membrane turnover (endocytosis) in ribosome-rich cells of the epithelium,
     which correlates pos. with water transport through the membrane.
ST   vasopressin antagonist inner ear disorder; endolymphatic sac
     vasopressin V2 receptor antagonist; water transport endolymphatic sac
     vasopressin; vertigo vasopressin V2 receptor antagonist;
     deafness vasopressin V2 receptor antagonist; tinnitus
     vasopressin V2 receptor antagonist
IT   Vasopressin receptors
     RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
     (Biological study); PROC (Process)
        (V2; use of vasopressin antagonists to treat inner ear
        disorders)
IT   Porins
     RL: BSU (Biological study, unclassified); BIOL (Biological study)
        (aquaporins, 2, expression of gene for, in endolymphatic sac,
        vasopressin effect on; use of vasopressin antagonists to treat inner
        ear disorders)
IT   Endocytosis
        (by endolymphatic sac, vasopressin effect on; use of vasopressin
        antagonists to treat inner ear disorders)
IT   Toxins
     RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
        (cholera, endocytosis by endolymphatic sac inhibition by; use of
        vasopressin antagonists to treat inner ear disorders)
IT   Organelle
        (coated pit, of endolymphatic sac, vasopressin effect on; use of
        vasopressin antagonists to treat inner ear disorders)
IT   Edema
        (dropsy, endolymphatic; use of vasopressin antagonists to treat inner
        ear disorders)
IT   Ear
        (endolymph, hydrops; use of vasopressin antagonists to treat
        inner ear disorders)
IT   Gene
        (expression; of aquaporin-2 and vasopressin V2 receptor genes in
        endolymphatic sac; use of vasopressin antagonists to treat inner
        ear disorders)
IT   Ear
        (inner, diseases; use of vasopressin antagonists to treat inner
        ear disorders)
IT   Hearing
        (loss; use of vasopressin antagonists to treat inner ear
        disorders)
IT   Ear
        (tinnitus; use of vasopressin antagonists to treat inner
        ear disorders)
IT   Dizziness
        (use of vasopressin antagonists to treat inner ear disorders)
IT   Peptides, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
   (vasopressin receptor antagonists; use of
   vasopressin antagonists to treat inner ear disorders)
IT 11000-17-2, Vasopressin
    RL: BSU (Biological study, unclassified); BIOL (Biological study)
       (antagonists; use of vasopressin antagonists to treat inner ear
       disorders)
IT 113-79-1, Arginine-vasopressin
    RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
    (Biological study); PROC (Process)
       (binding to receptors in endolymphatic sac; use of vasopressin
       antagonists to treat inner ear disorders)
IT 66575-29-9, Forskolin
    RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
       (endocytosis by endolymphatic sac inhibition by; use of vasopressin
       antagonists to treat inner ear disorders)
IT 112465-01-7 137975-06-5, OPC 31260 185913-79-5, SR 121463A
    RL: BAC (Biological activity or effector, except adverse); BSU (Biological
    study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
    (Uses)
       (vasopressin receptor antagonist; use of
       vasopressin antagonists to treat inner ear disorders)
IT 120-72-9D, Indole, derivs.   264-54-0D, 1H-1-Benzazepine, deriv.
    RL: BAC (Biological activity or effector, except adverse); BSU (Biological
    study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
    (Uses)
       (vasopressin receptor antagonists; use of
       vasopressin antagonists to treat inner ear disorders)

=> DIS HIST

   (FILE 'HOME' ENTERED AT 13:22:53 ON 13 JUN 2005)

   INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CANCERLIT,
   CAPLUS, CEN, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL,
   EMBASE, ESBIOBASE, IFIPAT, IMSDRUGNEWS, IMSPRODUCT, IPA, JICST-EPLUS,
   KOSMET, LIFESCI, MEDICONF, MEDLINE, NAPRALERT, ..' ENTERED AT 13:23:05 ON
   13 JUN 2005

   INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CANCERLIT,
   CAPLUS, CEN, DDFB, DDFU, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL,
   EMBASE, ESBIOBASE, IFIPAT, IMSDRUGNEWS, IMSPRODUCT, IPA, JICST-EPLUS,
   KOSMET, LIFESCI, MEDICONF, MEDLINE, NAPRALERT, ...' ENTERED AT 13:23:14
   ON 13 JUN 2005
            SEA VASOPRESSIN RECEPTOR ANTAGONIST
            ----
        15   FILE ADISCTI
         5   FILE ADISINSIGHT
         3   FILE ADISNEWS
       238   FILE BIOSIS
        60   FILE BIOTECHNO
         4   FILE CANCERLIT
       313   FILE CAPLUS
        58   FILE DDFU
         3   FILE DISSABS
        65   FILE DRUGU
         1   FILE EMBAL

       506   FILE EMBASE
       108   FILE ESBIOBASE
        23   FILE IFIPAT
         2   FILE IMSDRUGNEWS
         2   FILE IPA
        16   FILE JICST-EPLUS
        27   FILE LIFESCI
       184   FILE MEDLINE
         5   FILE NLDB
        97   FILE PASCAL
         4   FILE PHARMAML
         2   FILE PHIN
       192   FILE SCISEARCH
        77   FILE TOXCENTER
        67   FILE USPATFULL
         8   FILE USPAT2
L1   QUE VASOPRESSIN RECEPTOR ANTAGONIST

   INDEX 'EMBASE, CAPLUS, BIOSIS, SCISEARCH, MEDLINE, ESBIOBASE, PASCAL,
   TOXCENTER, USPATFULL, DRUGU, BIOTECHNO, DDFU, LIFESCI, IFIPAT,
   JICST-EPLUS, ADISCTI, USPAT2, ADISINSIGHT, NLDB, CANCERLIT, PHARMAML,
   ADISNEWS, DISSABS, IMSDRUGNEWS, IPA, PHIN, EMBAL' ENTERED AT 13:24:16 ON
   13 JUN 2005
         SEA L1 AND (EAR OR VERTIGO OR TINNITUS OR HYDROPS)
         ----
        5   FILE EMBASE
        3   FILE CAPLUS
        1   FILE TOXCENTER
       13   FILE USPATFULL
        3   FILE IFIPAT
        3   FILE USPAT2
L2   QUE L1 AND (EAR OR VERTIGO OR TINNITUS OR HYDROPS)

   FILE 'USPATFULL, EMBASE, CAPLUS, IFIPAT, USPAT2, TOXCENTER' ENTERED AT
   13:25:42 ON 13 JUN 2005
L3   28 L2
L4   20 DUP REM L3 (8 DUPLICATES REMOVED)
L5   5 L4 AND (PD<20000703 OR PRD<20000703)

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                     ENTRY   SESSION
FULL ESTIMATED COST   37.50   40.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)   SINCE FILE   TOTAL
                                                     ENTRY   SESSION
CA SUBSCRIBER PRICE   -0.73   -0.73

STN INTERNATIONAL LOGOFF AT 13:29:34 ON 13 JUN 2005

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653adk

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR 7):2

* * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1   Web Page URLs for STN Seminar Schedule - N. America
NEWS 2   "Ask CAS" for self-help around the clock
NEWS 3   FEB 25   CA/CAPLUS - Russian Agency for Patents and Trademarks
                   (ROSPATENT) added to list of core patent offices covered
NEWS 4   FEB 28   PATDPAFULL - New display fields provide for legal status
                   data from INPADOC
NEWS 5   FEB 28   BABS - Current-awareness alerts (SDIs) available
NEWS 6   FEB 28   MEDLINE/LMEDLINE reloaded
NEWS 7   MAR 02   GBFULL: New full-text patent database on STN
NEWS 8   MAR 03   REGISTRY/ZREGISTRY - Sequence annotations enhanced
NEWS 9   MAR 03   MEDLINE file segment of TOXCENTER reloaded
NEWS 10   MAR 22   KOREAPAT now updated monthly; patent information enhanced
NEWS 11   MAR 22   Original IDE display format returns to REGISTRY/ZREGISTRY
NEWS 12   MAR 22   PATDPASPC - New patent database available
NEWS 13   MAR 22   REGISTRY/ZREGISTRY enhanced with experimental property tags
NEWS 14   APR 04   EPFULL enhanced with additional patent information and new
                   fields
NEWS 15   APR 04   EMBASE - Database reloaded and enhanced
NEWS 16   APR 18   New CAS Information Use Policies available online
NEWS 17   APR 25   Patent searching, including current-awareness alerts (SDIs),
                   based on application date in CA/CAplus and USPATFULL/USPAT2
                   may be affected by a change in filing date for U.S.
                   applications.
NEWS 18   APR 28   Improved searching of U.S. Patent Classifications for
                   U.S. patent records in CA/CAplus
NEWS 19   MAY 23   GBFULL enhanced with patent drawing images
NEWS 20   MAY 23   REGISTRY has been enhanced with source information from
                   CHEMCATS
NEWS 21   MAY 26   STN User Update to be held June 6 and June 7 at the SLA 2005
                   Annual Conference
NEWS 22   JUN 06   STN Patent Forums to be held in June 2005
NEWS 23   JUN 06   The Analysis Edition of STN Express with Discover!
                   (Version 8.0 for Windows) now available

NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT
              MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
              AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005

NEWS HOURS   STN Operating Hours Plus Help Desk Availability
NEWS INTER   General Internet Information

Enter NEWS followed by the item number or name to see news on that
specific topic.

   All use of STN is subject to the provisions of the STN Customer
   agreement. Please note that this agreement limits use to scientific
   research. Use for software development or design or implementation
   of commercial gateways or other similar uses is prohibited and may
   result in loss of user privileges and other penalties.

   * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:45:13 ON 13 JUN 2005

=> FIL REGISTRY
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                     ENTRY   SESSION
FULL ESTIMATED COST   0.21   0.21

FILE 'REGISTRY' ENTERED AT 13:45:23 ON 13 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 JUN 2005 HIGHEST RN 852100-26-6
DICTIONARY FILE UPDATES: 12 JUN 2005 HIGHEST RN 852100-26-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

   Please note that search-term pricing does apply when
   conducting SmartSELECT searches.

  ****
  *   *
  * The CA roles and document type information have been removed from *
  * the IDE default display format and the ED field has been added,   *
  * effective March 20, 2005. A new display format, IDERL, is now   *
  * available and contains the CA role and document type information. *
  *   *
  ****

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading H:\STN queries\09530693.str

ring nodes :

20 21 22 23 24 25 31 32 33 34 36 37 65 66 67 68 69
ring/chain nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 26 27 , 28 29
30 35 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56
57 58 59 60 61 62 63 64 70 71 72 73 74 75 76 77 78 79 80
ring/chain bonds :
1-3 1-8 1-76 2-3 2-9 3-4 4-5 5-6 5-7 9-11 9-15 10-11 10-16 11-12 12-
13 12-14 16-18 16-26 17-18 17-27 18-19 19-20 27-29 27-38 28-29 28-39
28-77 29-30 30-31 34-35 39-40 41-43 41-51 41-52 42-43 42-53 43-44 44-45
45-46 46-47 47-48 48-49 48-50 53-55 53-63 54-55 54-64 55-56 56-57 57-58
58-59 59-60 60-61 60-62 64-66 64-70 65-71 71-72 71-75 72-73 72-76 73-74
77-78 77-79 79-80
ring bonds :
20-21 20-25 21-22 22-23 23-24 24-25 31-32 31-37 32-33 33-34 34-36 36-37
65-66 65-69 66-67 67-68 68-69
exact/norm bonds :
1-3 3-4 4-5 9-11 10-16 11-12 12-13 12-14 16-18 17-27 18-19 19-20 27-29
28-77 29-30 30-31 39-40 41-43 42-53 43-44 44-45 45-46 53-55 54-64 55-56
56-57 57-58 64-66 66-67 71-72 72-73 73-74 77-79 79-80
exact bonds :
1-8 1-76 2-3 2-9 5-6 5-7 9-15 10-11 16-26 17-18 27-38 28-29 28-39 34-
35 41-51 41-52 42-43 46-47 47-48 48-49 48-50 53-63 54-55 58-59 59-60
60-61 60-62 64-70 65-66 65-69 65-71 67-68 68-69 71-75 72-76 77-78
normalized bonds :
20-21 20-25 21-22 22-23 23-24 24-25 31-32 31-37 32-33 33-34 34-36 36-37

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:CLASS 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS
27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:Atom 32:Atom 33:Atom 34:Atom
35:CLASS 36:Atom 37:Atom 38:CLASS 39:CLASS 40:CLASS 41:CLASS 42:CLASS
43:CLASS 44:CLASS 45:CLASS 46:CLASS 47:CLASS 48:CLASS 49:CLASS 50:CLASS
51:CLASS 52:CLASS 53:CLASS 54:CLASS 55:CLASS 56:CLASS 57:CLASS 58:CLASS
59:CLASS 60:CLASS 61:CLASS 62:CLASS 63:CLASS 64:CLASS 65:Atom 66:Atom
67:Atom 68:Atom 69:Atom 70:CLASS 71:CLASS 72:CLASS 73:CLASS 74:CLASS
75:CLASS 76:CLASS 77:CLASS 78:CLASS 79:CLASS 80:CLASS

L1   STRUCTURE UPLOADED

=> s 11 sam
SAMPLE SEARCH INITIATED 13:45:48 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   1734 TO ITERATE

 57.7% PROCESSED   1000 ITERATIONS   0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 32183 TO   37177
PROJECTED ANSWERS: 0 TO   0

L2   0 SEA SSS SAM L1

=> s 11 ful

FULL SEARCH INITIATED 13:45:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 33882 TO ITERATE

100.0% PROCESSED   33882 ITERATIONS   0 ANSWERS
SEARCH TIME: 00.00.01

L3   0 SEA SSS FUL L1

=>
Uploading H:\STN queries\09530693a.str

ring nodes :

20 21 22 23 24 25 31 32 33 34 36 37 63 64 65 66 67
ring/chain nodes :
1   2   3   4   5   6   7   8   9   10 11 12 13 14 15 16 17 18 19 26 27 28 29
30 35 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56
57 58 59 60 61 62 68 69 70 71 72 73 74
ring/chain bonds :
1-3 1-8 1-74 2-3 2-9 3-4 4-5 5-6 5-7 9-11 9-15 10-11 10-16 11-12 12-
13 12-14 16-18 16-26 17-18 17-27 18-19 19-20 27-29 27-38 28-29 29-30
30-31 34-35 39-41 39-49 39-50 40-41 40-51 41-42 42-43 43-44 44-45 45-46
46-47 46-48 51-53 51-61 52-53 52-62 53-54 54-55 55-56 56-57 57-58 58-59
58-60 62-64 62-68 63-69 69-70 69-73 70-71 70-74 71-72
ring bonds :
20-21 20-25 21-22 22-23 23-24 24-25 31-32 31-37 32-33 33-34 34-36 36-37
63-64 63-67 64-65 65-66 66-67
exact/norm bonds :
1-3 3-4 4-5 9-11 10-16 11-12 12-13 12-14 16-18 17-27 18-19 19-20 27-29
29-30 30-31 39-41 40-51 41-42 42-43 43-44 51-53 52-62 53-54 54-55 55-56
62-64 64-65 69-70 70-71 71-72
exact bonds :
1-8 1-74 2-3 2-9 5-6 5-7 9-15 10-11 16-26 17-18 27-38 28-29 34-35 39-
49 39-50 40-41 44-45 45-46 46-47 46-48 51-61 52-53 56-57 57-58 58-59
58-60 62-68 63-64 63-67 63-69 65-66 66-67 69-73 70-74
normalized bonds :
20-21 20-25 21-22 22-23 23-24 24-25 31-32 31-37 32-33 33-34 34-36 36-37

Match level :
1:CLASS   2:CLASS   3:CLASS   4:CLASS   5:CLASS   6:CLASS   7:CLASS   8:CLASS   9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS
18:CLASS 19:CLASS 20:Atom   21:Atom   22:Atom   23:Atom   24:Atom   25:Atom   26:CLASS
27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:Atom   32:Atom   33:Atom   34:Atom
35:CLASS 36:Atom   37:Atom   38:CLASS 39:CLASS 40:CLASS 41:CLASS 42:CLASS
43:CLASS 44:CLASS 45:CLASS 46:CLASS 47:CLASS 48:CLASS 49:CLASS 50:CLASS
51:CLASS 52:CLASS 53:CLASS 54:CLASS 55:CLASS 56:CLASS 57:CLASS 58:CLASS
59:CLASS 60:CLASS 61:CLASS 62:CLASS 63:Atom   64:Atom   65:Atom   66:Atom   67:Atom
68:CLASS 69:CLASS 70:CLASS 71:CLASS 72:CLASS 73:CLASS 74:CLASS

L4   STRUCTURE UPLOADED

=> s l4 sam
SAMPLE SEARCH INITIATED 13:46:56 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   6837 TO ITERATE

 14.6% PROCESSED   1000 ITERATIONS   0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                         BATCH   **COMPLETE**
PROJECTED ITERATIONS: 131783 TO   141697
PROJECTED ANSWERS: 0 TO   0

L5   0 SEA SSS SAM L4

=> s l4 ful
FULL SEARCH INITIATED 13:47:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 137293 TO ITERATE

100.0% PROCESSED 137293 ITERATIONS   0 ANSWERS
SEARCH TIME: 00.00.03

L6   0 SEA SSS FUL L4

=> log y
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                               ENTRY   SESSION
FULL ESTIMATED COST   323.09   323.30

STN INTERNATIONAL LOGOFF AT 13:47:07 ON 13 JUN 2005